Investigational Drug For Multiple Sclerosis
The FDA has announced that it is lifting the hold and cleared ImStem’s investigational drug IMS001 which utilizes AgeX’s pluripotent stem cell technology ESI-053, thus it will be allowed to be made available for the treatment of multiple sclerosis in clinical trial settings. “Since pluripotent stem cells are capable of differentiating into all human cell …